Outcomes of Patients with Myeloproliferative Neoplasms (MPN) after Interferon-Alpha (IFN) Therapy Discontinuation

被引：0
|
作者：
Soret, Juliette
Cassinat, Bruno
Chevret, Sylvie
Dosquet, Christine
Giraudier, Stephane
Verger, Emmanuelle
Maslah, Nabih
Parquet, Nathalie
Chomienne, Christine
Kiladjian, Jean-Jacques
机构：
来源：
BLOOD | 2016年 / 128卷 / 22期
关键词：
D O I：
10.1182/blood.V128.22.3106.3106
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3106
引用
收藏
页数：4
相关论文
共 50 条
  • [11] Interferon-alpha and the pathogenesis of myeloproliferative disorders
    IA Voutsadakis
    Medical Oncology, 2000, 17 : 249 - 257
  • [12] CURRENT TREATMENT OF PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS (MPN)
    Petrides, Petro E.
    LEUKEMIA RESEARCH, 2015, 39 : SS5 - SS5
  • [13] Interferon Alpha Therapy Increases Pro-Thrombotic Biomarkers in Patients with Myeloproliferative Neoplasms
    Faille, Dorothee
    Lamrani, Lamia
    Loyau, Stephane
    Huisse, Marie-Genevieve
    Bourrienne, Marie-Charlotte
    Alkhaier, Sawsaneh
    Cassinat, Bruno
    Boulaftali, Yacine
    Debus, Jerome
    Jandrot-Perrus, Martine
    Chomienne, Christine
    Dosquet, Christine
    Ajzenberg, Nadine
    CANCERS, 2020, 12 (04)
  • [14] BIOPSYCHOSOCIAL CONSEQUENCES OF INTERFERON-ALPHA (IFN-ALPHA) THERAPY IN PATIENTS WITH CHRONIC HEPATITIS C INFECTION
    Baranyi, A.
    Meinitzer, A.
    Stepan, A.
    Matejka, J.
    Stauber, R.
    Rothenhaeusler, H. -B.
    EUROPEAN PSYCHIATRY, 2011, 26
  • [15] The role of interferon-alpha in the treatment of myeloproliferative disorders
    Fiorani, C
    Tonelli, S
    Casolari, B
    Sacchi, S
    CURRENT PHARMACEUTICAL DESIGN, 1999, 5 (12) : 987 - 1013
  • [16] Interferon-Alpha in the Treatment of Philadelphia-Negative Chronic Myeloproliferative Neoplasms. Status and Perspectives
    Hasselbalch, Hans Carl
    Larsen, Thomas Stauffer
    Riley, Caroline Hasselbalch
    Jensen, Morten Krogh
    Kiladjian, Jean-Jacques
    CURRENT DRUG TARGETS, 2011, 12 (03) : 392 - 419
  • [17] Elders' chronic myeloproliferative diseases: Interferon-alpha therapy effectiveness and feasibility.
    Bagnato, A
    Centra, A
    Deriu, L
    BLOOD, 1996, 88 (10) : 3538 - 3538
  • [18] Incidence and Outcomes of Myeloproliferative Neoplasms (MPN) in Adolescents and Young Adults (AYAs)
    Pemmaraju, Naveen
    Kantarjian, Hagop M.
    Cortes, Jorge E.
    Quintas-Cardama, Alfonso
    Pierce, Sherry A.
    Verstovsek, Srdan
    BLOOD, 2012, 120 (21)
  • [19] INTERFERON-ALPHA THERAPY WITH AND WITHOUT INTERFERON-ALPHA PRIMING IN PATIENTS WITH CHRONIC HEPATITIS-B INFECTION
    CATTERALL, AP
    KING, R
    LAU, JYN
    DANIELS, HM
    ALEXANDER, GJM
    MURRAYLYON, IM
    WILLIAMS, R
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1993, 31 (05) : 777 - 782
  • [20] Perspectives on interferon-alpha in the treatment of polycythemia vera and related myeloproliferative neoplasms: minimal residual disease and cure?
    Hasselbalch, Hans Carl
    Holmstroem, Morten Orebo
    SEMINARS IN IMMUNOPATHOLOGY, 2019, 41 (01) : 5 - 19
12345